-
Cediranib (AZD2171) In Vitro Workflow
2026-09-01
Build a more informative angiogenesis assay with Cediranib (AZD2171), linking VEGFR pathway suppression to endothelial behavior and distinct growth-versus-death outcomes. This workflow combines dose response, pathway verification, and orthogonal viability measurements for stronger cancer research conclusions.
-
Plerixafor (AMD3100) for CXCR4 Research
2026-09-01
Plerixafor (AMD3100) gives researchers a reversible way to interrogate CXCL12/CXCR4 signaling across tumor, blood, and bone-marrow models. Its value is especially strong when receptor blockade must be paired with spatial imaging, chemotaxis assays, or cell-mobilization readouts rather than used as a single endpoint.
-
MCC950 sodium in NLRP3 Research Workflows
2026-08-31
MCC950 sodium, also known as CRID3 sodium salt, enables selective dissection of NLRP3 signaling across macrophage, peripheral immune-cell, and neuroinflammation models. This workflow-focused guide connects cytokine assays with the reference study’s astrocyte-phenotype findings and provides practical optimization strategies.
-
SERCA–ER Stress in HSC Mobilization
2026-08-31
Li and colleagues identify SERCA inhibition as an upstream route for enhancing hematopoietic stem cell mobilization. Using BHQ, in vivo mobilization assays, cell-based phenotyping, and pathway validation, the study links ER stress to reduced CXCR4 surface expression through the CaMKII–STAT3 axis.
-
ASCC3 Activation in Fragile X Syndrome: Study Insights
2026-08-30
This study identifies ASCC3-dependent ribosome-associated quality control as a previously underappreciated function of FMRP and shows that CRISPR activation of ASCC3 can improve molecular, synaptic, and behavioral phenotypes in Fmr1 knockout mice. The work provides a mechanistic framework for studying collided ribosomes in fragile X syndrome while presenting an early proof of concept rather than a clinical treatment strategy.
-
Naringin Targets VEGFC in NASH Fibrosis
2026-08-29
A 2026 Phytomedicine study identifies a hepatocyte-derived VEGFC–macrophage regulatory axis that links metabolic liver injury to inflammation and fibrosis. Combining a high-fat-diet mouse model, hepatocyte-specific Vegfc deletion, pharmacological VEGFR-3 blockade, human datasets, and cell-based assays, the authors show that naringin limits fibrosis partly by suppressing hepatocyte VEGFC and restoring macrophage phenotypic balance.
-
JC-1 Workflows for Mitochondrial Membrane Potential
2026-08-28
JC-1 converts mitochondrial membrane-potential changes into a practical red-to-green fluorescence ratio for apoptosis detection and cellular bioenergetics study design. This guide connects assay setup and troubleshooting with nanocrystal-enabled palbociclib delivery, helping researchers distinguish mitochondrial stress from nonspecific loss of cell viability.
-
KR-12–Cu(II) Binding: Methods and Findings
2026-08-28
A 2024 Dalton Transactions study combined GFN2-xTB/ALPB calculations with potentiometric titration and isothermal titration calorimetry to resolve how KR-12 interacts with Cu(II). The work identifies main-chain oxygen atoms as dominant coordination partners and highlights Asp26 and Arg29 as important contributors, providing a mechanistic framework for interpreting metal-dependent peptide behavior.
-
TRIB3, Ferroptosis, and Sunitinib Sensitivity in ccRCC
2026-08-27
The reference study identifies TRIB3 as a mediator of sunitinib resistance in clear cell renal cell carcinoma and links its depletion to ferroptosis through the SLC7A11/GPX4 pathway. Its findings suggest that suppressing TRIB3 may provide a mechanistically defined strategy for increasing drug sensitivity, although further validation is needed beyond the reported experimental models.
-
Patient-Derived Gastric Cancer Assembloids
2026-08-27
A 2025 study developed gastric cancer assembloids by combining patient-matched tumor organoids with tumor-derived stromal subpopulations. The model reproduced stromal effects on gene expression and drug sensitivity, providing a more physiologically relevant platform for studying tumor–stroma interactions and personalized treatment responses.
-
K1301 Streptavidin Magnetic Beads for SNORA38B
2026-08-26
Discover how Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) can support mechanistic assays surrounding the SNORA38B–E2F1–GAB2 axis in non-small cell lung cancer. This article focuses on evidence-chain design, capture controls, and practical limitations rather than repeating general purification workflows.
-
PreScission Protease: Precise HRV 3C Tag Cleavage
2026-08-26
PreScission Protease is a recombinant HRV 3C protease–GST fusion for sequence-specific removal of affinity tags from recombinant proteins. Its defined Gln–Gly cleavage site and reported 4 °C operating condition support native-protein recovery when construct design and buffer compatibility are controlled.
-
JZL184: A Mechanistic Map of Endocannabinoid Pain
2026-08-25
Explore how JZL184, a selective monoacylglycerol lipase inhibitor, connects 2-AG metabolism with synaptic, sensory, and affective pain assays. This article translates recent CBD pain findings into practical decisions for endocannabinoid research.
-
Wortmannin: PI3K Inhibitor Workflow and Applications
2026-08-25
Wortmannin combines nanomolar PI3K inhibition with a practical role in signaling, autophagy, apoptosis, cancer, and host–pathogen studies. This guide translates its mechanism into dose-timing experiments, viral-entry assays, and troubleshooting strategies that distinguish pathway effects from solvent, cytotoxicity, and off-target artifacts.
-
Pazopanib Hydrochloride: Mechanism to Translation
2026-08-24
Pazopanib Hydrochloride is more than an anti-angiogenic agent: its multi-kinase profile creates a strategic opportunity to connect vascular biology, tumor-cell response, and assay design. This thought-leadership perspective outlines how translational researchers can extract more reliable insight from GW786034 studies.